Zobrazeno 51 - 60
of 85
pro vyhledávání: '"Marlana Orloff"'
Autor:
Curtis Johnston, Takami Sato, Marlana Orloff, Mizue Terai, David Arguello, Zoran Gatalica, Michael J. Mastrangelo, Ryan M. Weight, Asad Javed
Publikováno v:
Immunotherapy. 9(16)
Aim: To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). Materials & methods: A total of 295 MCM and 78 MUM specimens were analyzed for tumor cell PD-L1 expression. Additionally, 91 MCM and 45
Autor:
Leonel Hernandez-Aya, Pippa Corrie, M Sznol, Richard D. Carvajal, Namir J. Hassan, Jeff Evans, Middleton, Omid Hamid, C Mulatero, Alexander N. Shoushtari, Cheryl McAlpine, David Krige, Neil Steven, Joseph J. Sacco, N Little, J. R. Infante, Marlana Orloff, CM Coughlin, Takami Sato, Paul Nathan, Sandip Pravin Patel, A-M Hulstine
Publikováno v:
Journal for ImmunoTherapy of Cancer. 5
Publikováno v:
Expert Opinion on Investigational Drugs. 24:993-997
Treatment of advanced and metastatic melanoma is a rapidly changing field. Over the past 10 years, there have been six new drugs approved by the FDA for the treatment of metastatic melanoma. These approved drugs include a number of immune checkpoint
Publikováno v:
Clinical Cancer Drugs. 2:29-37
Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls
Autor:
Matias E, Valsecchi, Marlana, Orloff, Rino, Sato, Inna, Chervoneva, Carol L, Shields, Jerry A, Shields, Michael J, Mastrangelo, Takami, Sato
Publikováno v:
Ophthalmology. 125(2)
To compare overall survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with institutional controls.Retrospective cohort.Selection criteria were (1) monosomy 3 and 8q amplification by cytogenetic or DecisionDx-UM
Autor:
Marlana Orloff
Publikováno v:
Oncolytic Virotherapy
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added ye
Autor:
Mizue Terai, Meggie Danielson, Emma Link, David J. Eschelman, Rober D. Adamo, Takami Sato, Carin F. Gonsalves, Marlana Orloff
Publikováno v:
Cancer Research. 79:4052-4052
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Despite successful treatments for primary UM, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Treatment options are limited after dev
Autor:
Marlana Orloff, Samuel Pan, Richard D. Carvajal, Jessica Yang, Takami Sato, Paul Nathan, Karla A. Lee, Susana Hernandez, Shahnaz V. Singh-Kandah, Jose Lutzky, Leonel Hernandez-Aya, Sophie Merrick, Alexandra Nesson, Joseph J. Sacco, Mark R. Middleton
Publikováno v:
Journal of Clinical Oncology. 37:9592-9592
9592 Background: ICI responses in UM are rare (~5% with anti-CTLA4/PD1 monotherapy; 10-12% with combination ICI). IMC is a bispecific agent composed of a high affinity T cell receptor targeting the gp100 melanoma antigen fused to an anti-CD3 scFv tha
Publikováno v:
Indian Journal of Ophthalmology, Vol 67, Iss 12, Pp 2071-2073 (2019)
Indian Journal of Ophthalmology
Indian Journal of Ophthalmology
A 60-year-old Caucasian female was referred for biopsy-proven amelanotic orbito-conjunctival melanoma. Map biopsies revealed residual invasive melanoma on the deep tarsal margin at the site of previous surgery. Repeat excisions were required after re
Publikováno v:
Reviews on recent clinical trials. 11(2)
The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the Ch